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ABSTRACT 
Background: Sub-Saharan Africa has been greatly affected by the HIV epidemic, with an estimated 23.5 
million people living with HIV/AIDS (PLWHA) residing within this region by the end of 2011, being the 
leading course of morbidity and mortality. Tanzania is one of the countries in this region with an HIV 
prevalence of 5.7% i.e approximately 2.7 million PLWHA. The most common opportunistic infection in 
sub-Saharan Africa is tuberculosis (TB). Currently HIV and TB are the leading cause of morbidity and 
mortality in Tanzania. The management of these two infections in individuals with the dual infection is 
challenging due to drug-drug interactions that could potentially lead to toxicities or ineffective treatment 
outcomes for one or both diseases. This thesis aims to describe the socio-demographic and clinical 
characteristics as well as the clinical outcomes of treatment.  
Methods: We first performed a baseline study of a clinical HIV infected population enrolled at the HIV 
care and treatment centre (CTC) at Muhimbili National Hospital between June 2004 and September 
2008. Based on this clinical experience, a cohort of HIV infected patients, with or without TB who were 
HAART naïve with CD4 cell counts <200cells/ µL were recruited and followed up for 48 weeks after 
HAART initiation. Demographic, clinical and laboratory data were collected at baseline and up to 48 
weeks of HAART therapy. Plasma efavirenz concentrations and CYP2B6*6, CYP3A5*3,*6 and *7, 
ABCB1 and SLCO1B1 genotypes were determined. A 29-item questionnaire on neuropsychiatric 
manifestations was collected up to week 16 of follow up. 
Results: Most patients presenting to the CTC had advanced immune deficiency. Significantly higher 
proportions were female patients. With the free access to HAART in the later years, patients presented 
earlier to the CTC in the course of HIV disease. For the co-infection cohort study a total of 255 HIV only 
patients and 231 HIV-TB patients were recruited. The HIV-TB patients had significantly lower body 
mass index, Karnofsky scores and haemoglobin compared to those with HIV only, despite similar 
baseline CD4 cell counts. Mortality was similar in both the HIV only and those with HIV-TB, being 
10.9% (16 deaths/100person years) and 11.3% (17 deaths/100py) respectively with the predictors for 
mortality being advanced disease such as low CD4 counts, low baseline WBC, oral candidiasis and 
Kaposis sarcoma. HIV only patients had significantly higher plasma efavirenz concentrations compared 
to the HIV-TB patients 4 weeks after HAART initiation indicating an interaction with rifampicin. Female 
gender and those with CYP2B6*6/*6 genotype also had significantly higher plasma efavirenz 
concentrations. Pharmacogenetic variants play a role in plasma efavirenz concentrations and long-term 
efavirenz autoinduction. The proportion of patients with efavirenz concentrations below the therapeutic 
range (<1µg/ml) at week 16 was higher compared to the concentrations at week 4 predominantly 
affecting extensive metabolizers showing that efavirenz autoinduction continues up to week 16. The 
incidence of drug induced liver injury (DILI) was 7.8% being non-significantly higher in the HIV-TB 
patients compared to those with HIV only. The median time to DILI was 2 weeks and the predictors for 
DILI included CYP2B6*6/*6 genotype and a positive antibody result to hepatitis C infection, but not 
efavirenz concentrations. The overall incidence of neuropsychiatric manifestations was 57% and these 
were higher in the HIV only compared to those with HIV-TB (66.7% vs 47.4%). The HIV only patients 
were more symptomatic, with proportionately higher grades of manifestations compared to those with 
HIV-TB. The risk of neuropsychiatric manifestations was 3 times higher in HIV only compared to those 
with HIV-TB. There were comparable increases in the median body weight and median CD4 cell counts 
towards the end of the study between the HIV only and those with HIV-TB. A total of 11.7% (11 HIV 
only and 8 HIV-TB) of the patients were defined to have treatment failure. 
Conclusion: Patients enrolled at the CTCs are predominantly females, and present with advanced 
immune deficiency that ultimately puts them at a higher risk of dying. Pharmacogenetic variants 
influence efavirenz concentrations where slow metabolizers are at a higher risk of presenting with higher 
efavirenz concentrations, DILI and neuropsychiatric manifestations. The DILI seen in our setting is mild, 
transient and does not require treatment interruption. Patients using efavirenz alone are at a higher risk of 
developing neuropsychiatric manifestations compared to those who concomitantly use rifampicin. The 
WHO recommended efavirenz dosage of 600mg daily can be used with rifampicin among Tanzanian 
patients without compromise to their treatment outcomes.  
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1 INTRODUCTION 
1.1 HIV 
1.1.1 History and Epidemiology of HIV 
“31 years after the first reported cases of the acquired immunodeficiency syndrome 
(AIDS) and 29 years after the discovery of the etiologic agent, effective control of the 
HIV and AIDS pandemic remains elusive”. 
 
In June 1981, a new syndrome later coined “Acquired Immune Deficiency syndrome” 
(AIDS) was first announced by the Centre for Disease Control (CDC) [1, 2]. By 1983, 
the etiological agent for AIDS was identified and later named as human 
immunodeficiency virus (HIV) [3]. HIV disease pathogenesis is complex and 
multifactorial [4, 5]. Following primary infection with HIV, a burst of viral replication 
disseminates the virus into the lymphoid organs [6, 7]. A robust cellular and humoral 
immune response usually inhibits viral replication within weeks, but the virus 
invariably escapes from the immune containment, producing a chronic persistent 
infection leading to advanced clinical disease [8, 9].  A subspecies of chimpanzees 
native to west equatorial Africa had been identified as the original source of the virus. 
Scientists believe that the chimpanzee version of the immunodeficiency virus (called 
simian immunodeficiency virus or SIV) was transmitted to humans and mutated into 
HIV when humans hunted these chimpanzees for meat and came into contact with their 
infected blood [10-12]. 
 
There are two types of HIV: HIV-1 and HIV-2. Both types are transmitted by sexual 
contact, through blood, and from mother to child (more so for HIV-1 than HIV-2), and 
they appear to cause clinically indistinguishable AIDS. However, it seems that HIV-2 
is less easily transmitted, and the period between initial infection and illness is longer in 
the case of HIV-2. Worldwide, the predominant virus is HIV-1, and the relatively 
uncommon HIV-2 type is concentrated in West Africa and is rarely found elsewhere. 
The strains of HIV-1 can be classified into four groups: the "major" group M, the 
"outlier" group O and two new groups, N and P. These four groups may represent four 
separate introductions of simian immunodeficiency virus (SIV) into humans. More than 
90 percent of HIV-1 infections belong to HIV-1 group M. Within group M there are 
known to be at least nine genetically distinct subtypes (or clades) of HIV-1. These are 
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subtypes A, B, C, D, F, G, H, J and K [13-15]. Occasionally, two virus subtypes can 
meet and mix their genetic material in the cell of an infected person to create a new 
hybrid virus [16]. Those that infect more than one person are known as "circulating 
recombinant forms" [17]. Several studies have demonstrated that HIV-1 subtypes are 
not randomly distributed around the globe but show distinct geographical distributions 
[18-23]. The resultant viral diversity could have potential implications for possible 
differential rates of transmission, disease progression, responses to antiretroviral 
therapy (ART) and vaccine development [24, 25]. Worldwide it has been shown that 
48% of infections are caused by subtype C, 12% by subtype A, 11% by subtype B, 5% 
by subtype G, 2 % by subtype D and 22% recombinants [26]. 
 
At the end of 2010, an estimated 34 million people were living with HIV/AIDS 
(PLWHA) globally, including 3.4 million children less than 15 years. There were 2.7 
million new HIV infections in 2010, including 390,000 among children less than 15 
years [27]. Globally, the annual number of people newly infected with HIV continues 
to decline, although there is stark regional variation. Between 2001 and 2009, the 
incidence of HIV infection has declined in 33 countries, 22 of them in sub-Saharan 
Africa. These trends reflect a combination of factors: the natural course of HIV 
epidemics, behavioural changes associated with greater awareness about the effects of 
the epidemics and with intensified prevention efforts and increasing coverage of 
antiretroviral therapy [28].  
 
Sub-Saharan Africa remains the region most heavily affected by HIV. In 2010, about 
68% of all PLWHA resided in sub-Saharan Africa, a region with only 12% of the 
global population. Sub-Saharan Africa also accounted for 70% of new HIV infections 
in 2010 [28]. The total number of new HIV infections in sub-Saharan Africa has 
dropped by more than 26% per year, down to 1.9 million from the estimated 2.6 million 
at the height of the epidemic in 1997. 
 
1.1.2 Transmission of HIV, the symptoms and signs 
The HIV/AIDS pandemic consists of many separate epidemics. Each epidemic has its 
own distinct origin, in terms of geography and specific populations affected, and 
involve different types and frequencies of risk behaviours and practices. HIV is 
transmitted through unprotected sexual intercourse (anal or vaginal), transfusion of 
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contaminated blood, sharing of contaminated needles, and from a mother to her infant 
during pregnancy, childbirth and breastfeeding [29]. Physiologically, women are up to 
four times more vulnerable to HIV infection than men. There are several reasons. 
Infected semen remains in the cervix for some time, there is a large surface area in the 
vagina and cervix exposed to the virus, and the vagina is more susceptible to small tears 
during sex. Young women’s cervixes are even more vulnerable, particularly when they 
first start having sex.  
 
After entry of HIV into host cells using the reverse transcriptase enzyme of the host, the 
viral genome copies itself from RNA (ribonucleic acid) to DNA (deoxyribonucleic 
acid) genetic material. The viral DNA copy enters the host cell nucleus and 
incorporates itself into the cells own DNA using integrase enzyme, making the virus a 
part of the host cell nuclear protein. It thus establishes a latent infection for the rest of 
the life of the infected individual. HIV is then activated to produce new virions 
whenever the infected CD4 cell is activated. An HIV coded protease is active in the 
maturation of the virions at the cell surface. This viral production disturbs CD4 cell 
function and eventually exhausts the CD4 cells leading to increased immunodeficiency 
and increased vulnerability to opportunistic infections and death. 
The symptoms of HIV vary depending on the stage of infection. Though people living 
with HIV tend to be most infectious in the first few months, many are unaware of their 
status until later stages. The first few weeks after initial infection, individuals may 
experience no symptoms or a flu-like illness including fever, headache, rash or sore 
throat. 
As the infection progressively weakens the person’s immune system, the person 
becomes more susceptible to infections and the individual can develop other signs and 
symptoms such as swollen lymph nodes, weight loss, fever, diarrhoea and cough. They 
could also develop severe illnesses such as tuberculosis (TB), cryptococcal meningitis, 
and cancers such as lymphomas and Kaposi’s sarcoma. The most advanced stage of 
HIV infection is AIDS. It can take 10-15 years for an HIV-infected person to develop 
AIDS. 
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1.1.3 Diagnosis of HIV 
The World Health Organization (WHO) recommends the use of immunological assays 
for the diagnosis of HIV [30, 31]. Immunological assays include positive results from 
an HIV antibody screening test (e.g., reactive enzyme immunoassay [EIA]) confirmed 
by a positive result from a supplemental HIV antibody test (e.g., Western blot or 
indirect immunofluorescence assay test). Rapid tests are EIAs that do not have to be 
repeated but require a confirmatory test if reactive. In children less than 18 months of 
age virological assays can be used for screening to determine HIV infection against the 
background of antibodies transmitted from the mother [32].  
 
1.1.4 Treatment of HIV 
The most advances in HIV treatment have come from inhibiting the activity of enzymes 
used by the HIV in its life cycle. Antiretroviral drugs are broadly classified by the 
phase of the HIV life cycle that the drug inhibits. Entry or fusion inhibitors interfere 
with the binding, fusion and entry of HIV into the host cell. The CCR5 receptor 
antagonists do not target the virus directly; rather they bind to the CCR5 receptor on the 
surface of the CD4 T-cell thereby blocking viral attachment to the cell. Nucleoside 
reverse transcriptase inhibitors (NRTI) inhibit reverse transcription by incorporating 
themselves into the newly synthesized viral DNA strand as faulty nucleotides. Unlike 
NRTI which act as competitive substrate inhibitors, the non- nucleoside reverse 
transcriptase inhibitors (NNRTI) are non-competitive inhibitors of reverse transcriptase 
enzyme. The protease inhibitors (PI) act by targeting the viral assembly thereby 
inhibiting the activity of the protease enzyme which is essential in the final assembly of 
new virions. Integrase inhibitors inhibit the integrase enzyme which is responsible for 
integration of the viral DNA into the DNA of the infected host cell. The maturation 
inhibitors inhibit the last step in gag processing in which the viral capsid polyprotein is 
cleaved, thereby blocking the conversion of the polyprotein into the mature capsid 
protein (p24). 
In 1987, the U.S. Food and Drug Administration (FDA) approved the first antiviral 
drug zidovudine (ZDV; AZT) for use in preventing HIV replication by inhibiting the 
activity of the reverse transcriptase enzyme. This was used as a monotherapy for 
several years with very limited efficacy and later it was successfully paired with 
lamivudine (3TC) and used as combination therapy. The discovery of other classes of 
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antiretroviral drugs and potential development of resistance and cross-resistance to 
monotherapy warranted a switch from monotherapy to combination therapy. The 
introduction of viral load determination was crucial to prove this concept. This switch 
to combination antiretroviral therapy – highly active antiretroviral therapy (HAART) 
has had dramatic effects because the use combination therapy prevents mutated forms 
of HIV from evolving. 
Currently there are six classes of antiretrovirals with over 26 different drugs used for 
treatment of HIV. These drugs are aimed at stopping HIV in its tracks by stopping the 
various stages of viral replication. These classes include nucleoside reverse 
transcriptase inhibitors (NRTI’s), non-nucleoside reverse transcriptase inhibitors 
(NNRTI’s), protease inhibitors (PI’s), fusion inhibitors, CCR5 antagonists and 
integrase inhibitors [33-35]. By the end of 2010, WHO reported that 6,650,000 people 
were receiving antiretroviral therapy in low- and middle-income countries, accounting 
for 47% coverage of the estimated 14.2 million people eligible for treatment [27]. 
 
Guidelines have been set forth by the WHO and each individual country on how to use 
and manage patients on HAART [34]. WHO currently recommends HAART initiation 
for all PLWHA with a CD4 count of ≤350 cells/mm3 and for those with WHO clinical 
stage 3 or 4 if CD4 testing is not available. The Tanzanian guidelines based on WHO 
recommended first-line therapy consist of an NNRTI + two NRTIs, one of which 
should be zidovudine (AZT) or tenofovir (TDF). Countries have been advised to reduce 
the use of stavudine (d4T) in first-line regimens because of its well-recognized 
toxicities. Second-line HAART consists of a ritonavir-boosted protease inhibitor (PI) 
plus two NRTIs, one of which should be AZT or TDF, based on what was used in first-
line therapy. Ritonavir-boosted atazanavir (ATV/r) or lopinavir/ritonavir (LPV/r) are 
the preferred PIs [34]. 
 
1.1.5 Preventive measures for HIV 
The rate of new HIV infections and AIDS-related deaths has fallen globally resulting in 
a decline of the epidemic. Declines in new HIV infections across the world have been 
spurred by access to antiretroviral therapy and the changes in behaviour via several 
intervention programs. The most dramatic increases in antiretroviral therapy coverage 
have occurred in sub-Saharan Africa, with a 20% increase between 2009 and 2010 
alone. The best success seen is in programs to prevent the transmission of HIV from 
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mothers to children, which can reduce rates of transmission by 92-99% [36, 37]. This 
primarily involves the use of a combination of antiretrovirals during pregnancy and 
after birth in the infant but also potentially include bottle-feeding rather than 
breastfeeding. As of 2012 there is no effective vaccine for HIV or AIDS. However 
further research is on-going in search of a truly effective vaccine [38, 39]. Social 
strategies have proved effective in changing people’s behaviour including sex 
education, provision of condoms both male and female, needle exchange programs, 
HIV testing centres, treatment of sexually transmitted infections (STI’s) and the use of 
social media to educate people. These strategies have widely differing levels of efficacy 
and social acceptance. 
 
Other interventions include advocating male circumcision and the potential use of an 
antiretroviral based vaginal gel. Circumcision in men has been shown to reduce the risk 
of HIV infection in heterosexual men by between 38-66% [40]. More than 550,000 
males were circumcised for HIV prevention in the priority countries of sub-Saharan 
Africa by the end of 2010. Based on these studies, the WHO and UNAIDS both 
recommended male circumcision as a method of preventing female-to-male HIV 
transmission in 2007 [41]. Provision of HAART as pre-exposure prophylaxis has been 
shown to protect 96% of partners of HIV infected individuals [37, 42, 43]. Post 
exposure prophylaxis with HAART is also recommended following needle-stick 
injuries or exposure to body fluids within the health care environment and to sexual 
assault victims. A vaginal gel containing tenofovir, a reverse transcriptase inhibitor, 
when used immediately before sex, reduces infection rates by approximately 40% 
among Africa women [44]. 
 
1.2 HIV IN TANZANIA 
The first 3 patients with AIDS were reported from a hospital in the north-western 
region of Kagera in November 1983 [45, 46]. The patients’ clinical features were 
similar to those reported in neighbouring countries with extreme wasting (Slim 
disease). The AIDS cases subsequently reported were among young adults, both males 
and females who were involved in cross-border trade, commercial sex workers and 
truck drivers. Due to constant movement this group accelerated HIV transmission to 
other parts of the country. By the end of 1985, these cases were tested by the newly 
developed Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot assay 
and confirmed to be infected with HIV. By 1986 many regions in Tanzania had 
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reported AIDS cases to the Ministry of Health [47, 48].  
 
The epidemic of AIDS and HIV infection in Tanzania is associated solely with HIV-1. 
In Tanzania HIV-1 subtypes A, C and D have been documented as major circulating 
strains [49-54]. The proportion of HIV subtype circulating recombinant forms in the 
country has also been increasing with studies reporting up to 27% recombinants [55-
57]. More than 60% of detected recombinants are those of the subtype C that differs 
from neighbouring Kenya and Uganda that commonly have recombinants of A and D 
[58, 59].  
 
The estimated prevalence of HIV when it was first identified in the mid 1980’s was 
1.3%. The prevalence gradually increased reaching its peak at 7.2% in 2003-2004, after 
which there has been a steady decline in the country’s HIV prevalence [60, 61]. The 
current prevalence of HIV in Tanzania is estimated at 5.7%, and it is higher among 
women (6.6%) compared to men (4.4%) [62]. Data suggest that the most important 
factor fuelling the HIV epidemic in the country is unprotected heterosexual intercourse, 
which constitutes about 80% of all new infections while approximately 18% of 
infections are accounted for by mother to child transmissions [63]. 
 
Provision of free HAART at Care and treatment Centres (CTC) was rolled out country 
wide in October 2004. By the end of 2005, there were a total of 96 CTCs providing 
HAART, increasing to 825 in December 2010 [64]. By the end of 2010, the cumulative 
number of clients enrolled in HIV care was 740,040. A total of 244,148 patients were 
on ART. Of those, 92.2% were adults (>15 years) with majority of the patients (71.6%) 
being in the age group 25 – 49 years, with 7.8% being in those below 15 years, while 
the age group 15 – 24 years contributed the least proportion (4.4%) [64]. 
 
Following recommendations from WHO for treatment guidelines, the Ministry of 
Health and Social Welfare (MoHSW) together with the National AIDS Control 
Program (NACP) have come up with treatment guidelines tailored for Tanzania [34, 
65]. According to these guidelines the MoHSW recommends all patients to be given 
triple therapy comprising of 2 NRTI + 1 NNRTI or 2 NRTI + 1 PI or 3 NRTI’s. The 
default first line regimen is the use of 2 NRTI + 1 NNRTI and this is commonly 
zidovudine (300mg) + lamivudine (150mg) + efavirenz (600mg). Patients receive their 
HAART from the CTC on a monthly basis [65]. 
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Tanzania, like many other countries around the world, is taking action to try and 
decrease the number of HIV infections. Voluntary Counselling and Testing (VCT) is 
the predominant approach in mass HIV testing in Tanzania and this accounts for 
approximately 86% of referral of patients to CTCs. Condom promotion and distribution 
along with sex education has been advocated in most parts of the country. Free 
HAART is given as part of Prevention of Mother to Child Transmission (PMTCT), 
along with pre- and post-exposure prophylaxis to persons at risk. Male circumcision in 
Tanzania has a prevalence of 67%. Following the 2007 WHO recommendations, 
campaigns to circumcise men are on-going. There are several HIV vaccine trials 
ongoing in the country, which are mainly phase I/II trials like the HIVIS 03 and the 
TaMoVac 01 [66].  
 
 
1.3 TUBERCULOSIS 
1.3.1 History and Epidemiology of Tuberculosis 
“With 2 billion persons, a third of the world population, estimated to be infected with 
mycobacteria” [67]. 
 
The presence of tuberculosis (TB) can be traced back to centuries ago. In 2008, 
evidence for tuberculosis infection has been discovered in human remains from the 
Neolithic era dating from 9,000 years ago, in a settlement in the eastern Mediterranean 
[68]. Over time, tuberculosis was known by many names including Contagion, Phthisis 
and White Plague. Scientists such as Hippocrates and many other at the time believed 
death by tuberculosis was inevitable and that it was a contagious disease characterized 
by fever, colourless urine, cough resulting in a thick sputa, and loss of thirst and 
appetite [69]. It was not until 1882 when a physician Robert Koch utilized a new 
staining method and applied it to the sputum of tuberculosis patients, revealing for the 
first time the causal agent of the disease: Mycobacterium tuberculosis, or Koch's 
bacillus [70, 71]. He made his result public at the Physiological Society of Berlin on the 
24th of March 1882, in a famous lecture entitled Über Tuberculose, which was 
published three weeks later, and since then 24 March has been known as World 
Tuberculosis Day [70, 72]. 
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It was not until 1943, 60 years later, that the first effective anti-tuberculosis agent, 
streptomycin, was isolated and used for treatment of TB [73]. Although this 
monotherapy cured several people, a substantial number of people developed TB 
again (relapse) and later resistance to streptomycin was seen [74]. Streptomycin in 
combination with isonicotinic acid hydrazide (isoniazid) showed much better 
outcomes and after rifampicin was discovered in 1957 the TB treatment was 
revolutionized [75-77]. Ultimately, results of clinical trials led by the British Medical 
Research Council showed that a four-drug regimen was recommended for use in 
patients with newly diagnosed tuberculosis. The backbone of such empirical regimens 
was the combination of isoniazid and rifampicin, the most effective and reasonably 
well-tolerated oral agents [78].  
One in three people in the world is infected with Mycobacterium tuberculosis, however 
a relatively small proportion of infected people will go on to develop TB disease [79]. 
Despite the availability of highly efficacious treatment for decades, TB remains a major 
global health problem. In 1993, WHO declared TB a global public health emergency, at 
a time when an estimated 7–8 million cases and 1.3–1.6 million deaths occurred each 
year. There are 22 countries in the world which constitute 82% of global tuberculosis 
cases, and these are termed as 22 High-TB Burden Countries. There were an estimated 
8.8 million incident cases of TB (range, 8.5 million–9.2 million) globally in 2010 [80]. 
TB is the second leading cause of death from an infectious disease worldwide (after 
HIV), which caused an estimated 1.5 million deaths in 2010. Globally, the absolute 
number of incident TB cases per year has been falling at an approximate rate of 1.3% 
per year since 2002. Likewise TB mortality has also been falling globally [81]. In 2010, 
6.2 million people were diagnosed with TB and notified to national TB control 
programmes. Of these, 5.4 million had TB for the first time and 0.3 million had a 
recurrent episode of TB after being cured of TB in the past [80]. Globally, the ratio of 
female to male tuberculosis cases notified is 1/1.7 and 70% more smear-positive male 
than female tuberculosis patients are diagnosed every year and notified to the WHO 
[80]. 
 
1.3.2 Transmission of TB, the symptoms and signs  
Mycobacterium tuberculosis (rod-shaped, non–spore-forming, aerobic bacterium) is 
spread by small airborne droplets, called droplet nuclei, generated by the coughing, 
sneezing, talking, or singing of a person with pulmonary or laryngeal tuberculosis. The 
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number of bacilli in the droplets, the virulence of the bacilli, exposure of the bacilli to 
ultraviolet light, degree of ventilation, and occasions for aerosolization all influence 
transmission. Introduction of M tuberculosis into the lungs leads to infection of the 
respiratory system; however, the organisms can spread to other organs, such as the 
lymphatics, pleura, bones/joints, or meninges, and cause extrapulmonary tuberculosis. 
For persons with intact cell-mediated immunity, the next defensive step is formation of 
granulomas around the M tuberculosis organisms restricting growth and establishing 
latency, by undergoing fibrosis and calcification, successfully controlling the infection 
so that the bacilli are contained in the dormant, healed lesions [82]. Lesions in persons 
with less effective immune systems progress to primary progressive tuberculosis [83-
85]. Epidemiological information shows that there are differences between men and 
women in prevalence of infection, rate of progression from infection to disease, 
incidence of clinical disease, and mortality due to tuberculosis [86, 87]. 
About 90% of those infected with M. tuberculosis have latent TB infections which 
are asymptomatic with only a 10% lifetime chance of progression to active 
tuberculous disease [88]. Tuberculosis may infect any part of the body, but most 
commonly occurs in the lungs (known as pulmonary tuberculosis (PTB)) and 
approximately 15-20% of cases are termed Extrapulmonary TB (EPTB) when 
tuberculosis develops outside of the lungs [89]. General signs and symptoms include 
fever, chills, night sweats, loss of appetite, weight loss, and fatigue, and significant 
finger clubbing may also occur [90]. In patients with pulmonary TB along with the 
general symptoms they may also present with chest pains and coughing out blood.  
EPTB occurs more commonly in immunosuppressed persons, commonly HIV patients 
and in young children. Common sites for extrapulmonary infection include the pleura, 
central nervous system, lymphatic system, genitourinary system, and the bones and 
joints among others. A potentially more serious, widespread form of TB is called 
"Disseminated or Miliary TB” makes up about 10% of extrapulmonary cases. Other 
signs of EPTB depend on the affected organs.  
 
1.3.3 Diagnosis of TB 
Active TB may be considered as a possible diagnosis when patients present with 
physical signs and symptoms suggestive of TB plus abnormal findings on a chest 
radiograph. The radiographs may show the characteristic findings of infiltrates with 
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cavitation in the upper and middle lobes of the lungs; however atypical features may 
be seen in immunocompromised patients.  
Traditionally, in spite of modern advances, the first laboratory test used to detect active 
tuberculosis is microscopic examination of a sputum smear or other diagnostic 
specimen for the presence of acid-fast bacilli (AFB) using the Ziehl-Neelson staining. 
Definitive diagnosis of tuberculosis requires the identification of M. tuberculosis in a 
culture of a diagnostic specimen. Traditionally, culture has been grown on solid and 
liquid media such as Löwenstein-Jensen (LJ), or Kirchner and the various Middlebrook 
formulations. New fully automated systems that rely on non-radiometric detection of 
growth have been developed such as the MB/BacT (Biomerieux), BACTEC 9000 
(Becton Dickinson), and the Mycobacterial Growth Indicator Tube (MGIT; Becton 
Dickinson) [91]. Newer rapid automated DNA tests are being used for the diagnosis of 
TB along with drug susceptibility testing (Xpert MTB/RIF is a TB-specific, cartridge-
based nucleic amplification assay based on the GeneXpert multi-disease platform). 
 
Presumptive diagnosis of pulmonary TB can be made in patients with abnormal 
findings on a chest radiograph suggestive of TB, presenting with signs and symptoms 
of TB in spite of at least two sputum smear examinations negative for AFB. Diagnostic 
criteria should include: radiographic abnormalities consistent with active pulmonary 
TB; no response to a course of broad-spectrum antibiotics; and a decision by a clinician 
to treat with a full course of anti-TB chemotherapy. A patient with positive culture but 
negative AFB sputum examinations is also a smear-negative case of pulmonary TB. In 
patients with EPTB, diagnosis should be based on one culture-positive specimen or 
histological or strong clinical evidence consistent with active extrapulmonary disease, 
followed by a decision by a clinician to treat with a full course of anti-TB 
chemotherapy. Immunological diagnostic tests such as the Mantoux tuberculin skin test 
are of limited application due to cross reactivity and poor sensitivity.  
 
1.3.4 Treatment of TB 
Directly Observed Treatment, Short-course (DOTS) was adopted by WHO and 
implemented in several countries and has been the gold standard of treatment [92]. It is 
the most effective way to ensure rapid sputum conversion of infectious patients, 
thereby stopping further transmission of M. tuberculosis to the community. WHO 
advises that all TB patients should have at least the first two months of their therapy 
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observed (and preferably the whole of it observed): this means an independent observer 
watching patients swallow their anti-TB therapy. Treatment with properly implemented 
DOTS has a success rate exceeding 95%.  
WHO has set up guidelines whose principal purpose is to help national TB control 
programs (NTPs) in setting TB treatment policies. The first line drugs in the 
treatment of TB are rifampicin, isoniazid, ethambutol and pyrazinamide. The second 
line consists of 6 classes of drugs including aminoglycosides, polypeptides, 
fluoroquinolones and thioamides. TB treatment is divided into a 2 months intensive 
phase that comprises all the 4 first line anti-TB drugs followed by 4 months 
continuation phase with rifampicin and isoniazid (2HRZE/4HR). WHO now 
recommends a full 6 months of rifampicin will reduce the number of relapses and 
failures [93].  
However, despite all measures, the emergence multidrug-resistant tuberculosis (MDR-
TB) which is defined as tuberculosis that is resistant at least to isoniazid and rifampicin, 
the two most powerful first-line anti-TB drugs has been on the increase [94]. 
Worldwide, there were an estimated 650,000 MDR-TB cases in 2010. MDR-TB can 
develop in the course of the treatment of fully sensitive TB and this is always the result 
of patients missing doses or failing to complete a course of treatment, however, MDR-
TB strains appear to be less fit and less transmissible. For patients diagnosed with 
MDR-TB, WHO recommends treatment of at least 20 months with a regimen that 
includes second-line anti-TB drugs [93]. 
In 2006, WHO announced a new epidemic of Extensively Drug Resistant 
Tubercusosis (XDR-TB) from South Africa [95, 96]. XDR-TB is defined as TB that 
has developed resistance to at least rifampicin and isoniazid as well as to any member 
of the quinolone family and at least one of the following second-line anti-TB 
injectable drugs: kanamycin, capreomycin, or amikacin [95]. It is clear that the spread 
of this strain of TB is closely associated with a high prevalence of HIV and poor 
infection control.  
Currently the only available and most widely used vaccine is the Bacillus Calmette–
Guérin (BCG) which, while it is effective against disseminated disease in childhood, 
confers inconsistent protection against contracting pulmonary TB [97]. 
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1.4 TUBERCULOSIS IN TANZANIA 
Tanzania is one among the 22 high burden countries in the world for TB ranking 14th 
overall [80]. The National Tuberculosis and Leprosy Programme (NTLP) was launched 
by the Ministry of Health and Social Welfare in 1977 provide high quality and effective 
interventions to control TB and leprosy as a single combined programme [98]. The 
NTLP uses the gold standard DOTS strategy in the management of TB and to prevent 
development of anti-TB drug resistance. The first short-course regimen of 8 months 
was introduced in Tanzania in 1987 for sputum smear positive patients only. A six 
months short-course regimen for new smear positive, smear negative and 
extrapulmonary TB was introduced in 2006 in line with WHO recommendations [93, 
99]. NTLP is endeavouring to achieve the WHO targets for TB control of detecting 
70% of the infectious cases and treating successfully 85% of them based on Stop TB 
strategy of global TB control [81]. 
 
Tuberculosis continues to be among the major public health problems in the country, 
more than 20 years after launching of the programme. The number of tuberculosis 
cases has steadily increased from 11,753 in 1983 to about 65,665 in the year 2004, 
almost six-fold [99]. This rapid increase of tuberculosis in Tanzania is mainly attributed 
to the HIV epidemic affecting the young adult population aged 15-45 years, but factors 
like population growth and urban overcrowding have also contributed. Dar es Salaam, 
the country’s commercial capital contributes about 24% of all cases of TB in terms of 
absolute numbers [98].  
 
Reports from 2009 show that there were 64,267 cases notified of all forms of 
tuberculosis (new and re-treatment). Among those, 93% were new tuberculosis cases 
and 7% were re-treatment cases. Of the new cases 41.5% were smear positive, 36.2% 
smear negative and 22.3% had extra-pulmonary TB [98]. The ratio of male to female 
among new smear positive TB cases notified in 2009 was 1.7. Countrywide, the rate of 
treatment success for new smear positive TB cases was 88.3% making the country able 
to achieve the WHO global target of 85% success [98]. The mortality rate among TB 
patients on treatment was reported to be 3.6%. The prevalence of MTB strains resistant 
to any of the four first-line drugs in new patients was 8.3%, while the prevalence of 
MDR-TB was 1.1%. In retreatment patients, the crude prevalence for any resistance 
and for MDR-TB was respectively 20.6% and 3.9%. The low levels of drug resistance 
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in Tanzania are likely due to a well performing TB control programme and the absence 
of noticeable involvement of the private sector in TB treatment [100]. 
 
Starting from 2006 Tanzania introduced in a phased manner 4-drug fixed dose 
combinations (FDCs) for all TB patients in line with the WHO/IUATLD 
recommendations in order to improve overall results and reduce the risk of multi-drug 
resistance. New patients with pulmonary TB should receive a regimen containing 6 
months of rifampicin: 2HRZE/4HR [93, 99]. Three times weekly dosing throughout 
therapy [2(HRZE)x3/4(HR)x3] is another alternative provided that every dose is 
directly observed and the patient is not living with HIV or living in an HIV-prevalent 
setting. Retreatment patients will be provided with first line drugs plus streptomycin 
{2HRZES/1HRZE/5HRE].  
 
 
1.5 HIV AND TB CO-INFECTION 
1.5.1 Epidemiology of HIV and TB co-infection 
The HIV/AIDS epidemic is reviving the old TB problem in well-resourced countries 
and greatly worsening an existing problem in resource poor countries [28, 80]. HIV is 
the most important cause of the rapid increase of the current TB epidemic and both TB 
and HIV are fatally synergistic. TB is the leading infectious killer of PLWHA and the 
most common opportunistic infection (OI) [101, 102]. Almost one in four deaths that 
occurs among PLWHA is due to TB. HIV promotes both the progression of latent TB 
infection to active disease and a relapse of the disease in previously treated patients: 
individuals infected with M. tuberculosis who get infected with HIV have a 20-30 
times higher risk of developing tuberculosis disease than those who are HIV negative 
[103-106]. HIV affects the immune system and increases the likelihood of people 
acquiring new TB infections. TB may accelerate the progression of HIV from 
asymptomatic to symptomatic disease and even AIDS, increases both mortality and the 
incidence of other opportunistic infections among PLWHA [107].  
 
Globally the number of TB patients who had been diagnosed with HIV status reached 
2.1 million in 2010, equivalent to 34% of notified cases of TB. Of the 8.8 million 
incident cases globally an estimated 1.1 million (13%) were found to be co-infected 
with HIV [80]. Overall, the African region accounted for a staggering 82% of all new 
TB cases co-infected with TB. Among TB patients known to be living with HIV, 46% 
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globally and 42% in the African region were on in 2010 [80]. The number of PLWHA 
who were screened for TB was approximately 58%, among those who were enrolled in 
HIV care worldwide in 2010. The treatment success and death rates reported for HIV-
positive TB cases in 2009 were 72% and 20% respectively [80].  
 
Like other countries, Tanzania also bears the brunt of TB patients who are co-infected 
with HIV. Of the 64,267 notified TB cases, 87.5% were counselled and tested for HIV 
of whom 37.2% were found to be co-infected with HIV [98, 108]. Results from 19,940 
co-infected patients show that 86.6% were successfully treated, and 8.1% died during 
TB treatment while only a small proportion (0.2%) failed treatment. Approximately 
41.5% of the new TB cases had smear positive PTB, 36.2% were smear negative for 
PTB and 22.3% presented with extra-pulmonary TB [98]. Research has shown that 
patients with disseminated TB presented with features of reactivation and newly 
acquired TB [109]. A low prevalence of TB drug resistance has been seen hence giving 
hope to better TB treatment outcomes and ultimately HIV management [100, 110]. 
 
TB occurs earlier in the course of HIV infection than other opportunistic infections. It 
progresses faster and harder to diagnose among HIV infected people, and is likely to be 
fatal if undiagnosed or left untreated. Even among HIV-infected patients, PTB is still 
the commonest presenting feature, however, EPTB or sputum smear-negative TB is 
common especially as immunosuppression advances [111, 112]. The commonest forms 
of extra-pulmonary TB are: pleural effusion, lymphoadenopathy, pericardial disease, 
milliary disease, meningitis, Spinal TB (Pott’s disease) and disseminated TB. Case-
fatality is higher in people living with HIV with smear-negative pulmonary and 
extrapulmonary TB, as these patients are generally more immunosuppressed than those 
with smear-positive TB [113]. The case-fatality rate is reduced in patients who receive 
concurrent ART. High mortality rates have been reported among PLWHA who have 
drug-resistantTB [114], and rates can exceed 90% in patients co-infected with XDR-TB 
and HIV [115, 116]. Early detection and proper treatment of tuberculosis will therefore 
influence not only the life expectancy but also the quality of life of PLWHA. 
 
1.5.2 Treatment of HIV-TB co-infection 
Since the WHO declaration in 1993 that TB was a global emergency, the DOTS 
strategy has been the key public health intervention that has been widely used to affect 
global TB control [117]. Antiretroviral therapy improves survival in HIV-positive 
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patients and improves TB outcomes [118, 119]. In addition, antiretroviral therapy 
reduces TB rates by up to 90% at an individual level, by 60% at a population level and 
it reduces TB recurrence rates by 50% [120-123]. 
 
Unfortunately, drug-drug interactions between the current first-line TB regimen and 
certain commonly used antiretrovirals complicate treatment for co-infected patients. 
This potentially results in the loss of antiviral efficacy and the development of viral 
resistance [124]. Overlapping toxicities of anti-TB and antiretroviral agents occur 
frequently, necessitating discontinuation of therapy and increasing the risk of non-
adherence further fuelling the development of drug resistance for both anti-TB and 
HAART [125]. Immuno-pathological reactions, termed "the immune reconstitution 
inflammatory syndrome" (IRIS), occur frequently when antiretroviral therapy is 
initiated in patients with tuberculosis (paradoxical TB-associated IRIS), or in which 
HAART therapy results in new presentation of previously undetected (likely 
subclinical) TB infection (unmasking TB-associated IRIS). Reports estimating the 
prevalence of TB-IRIS in patients with undergoing new ARVs are variable, ranging 
from as low as 7.6% in one to as high as 32% [126, 127].  
 
WHO recommends that the first-line HAART regimen contain two nucleoside reverse 
transcriptase inhibitors (NRTIs) plus one non-nucleoside reverse transcriptase inhibitor 
(NNRTI) as in non-TB infected patients. The preferred NRTI backbone is zidovudine 
(AZT) or tenofovir disoproxil fumarate (TDF), combined with either lamivudine (3TC) 
or emtricitabine (FTC). For the NNRTI, WHO recommends efavirenz (EFV) due to 
fewer interactions compared to nevirapine [34, 93, 128]. The recommendations of 
WHO in 2009 are that TB treatment should be commenced first and ART subsequently 
commenced as soon as possible and within the first 8 weeks of starting TB treatment. 
When TB is diagnosed in patients already receiving HAART, TB treatment should be 
started immediately and HAART needs to be modified to prevent potential drug-drug 
interactions [93].  
 
In all HIV-positive TB patients, co-trimoxazole preventive therapy (CPT) should be 
initiated as soon as possible and given throughout TB treatment [129]. Co-trimoxazole 
preventive therapy substantially reduces mortality in HIV-positive TB patients [117, 
129]. 
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NTLP in line with WHO, UNAIDS and the Stop TB Partnership have set a target of 
reducing TB mortality rates among PLWHA by 50% by the year 2015 compared with 
rates in 2004. The recommended interventions are collectively known as collaborative 
TB/HIV activities. These activities include HIV testing of TB patients, provision of 
ART and CPT to TB patients living with HIV, intensified TB case-finding among 
people living with HIV, isoniazid preventive therapy (IPT) for PLWHA who do not 
have active TB, and infection control in health care and congregate settings (the latter 
three activities are referred to as the “Three Is for HIV/TB”) [130]. 
 
 
1.6 PHARMACOKINETICS AND PHARMACOGENETICS OF RIFAMPICIN 
AND EFAVIRENZ 
1.6.1 Drug-Drug Interactions 
Drug-drug interactions can occur when two or more drugs are used concurrently and 
produce either a synergistic or antagonistic effect. Drug-drug interactions can lead to 
changed systemic exposure, resulting in variations in drug response of the co-
administered drugs. There are a number of mechanisms by which drugs interact with 
each other, and most of them can be divided into two general categories: 
pharmacokinetic and pharmacodynamic interactions. With pharmacokinetic drug 
interactions, one drug affects the absorption, distribution, metabolism, or excretion of 
another. When pharmacodynamic drug interactions occur, two drugs have additive or 
antagonistic pharmacologic effects. Either type of drug interaction can result in adverse 
effects in some individuals. 
 
The potential for clinically important drug-drug interactions can often be predicted 
based on the drug properties, method of drug administration, and patient-specific 
parameters [131]. Recent scientific developments particularly in the area of cytochrome 
P450 drug metabolizing enzymes and of late the role of drug transporters have 
revolutionized the study of drug interactions. The result has been a deluge of published 
drug interaction research including databases that have information on potential drug 
interactions, and this has overwhelmed most health care practitioners. 
 
In the past decade, there have been numerous advances in HIV therapy which have 
turned it into a chronic and manageable disease. Patients often require treatment for co-
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morbid conditions as well as HIV, and consequently, pharmacokinetic interactions 
between HAART and other drug classes are an increasing concern [132, 133]. As a 
result, this could lead to viral breakthrough and development of resistance or sub-
optimal disease management, or supra-therapeutic levels which may result in drug 
toxicity and possibly non-adherence and/or increased morbidity [133]. The efficacy and 
toxicity of the interacting drug(s) may also be similarly affected. Management options 
may vary depending upon a number of factors including the mechanism and clinical 
consequences of the interaction, availability of therapeutic alternatives, patient 
convenience and cost. Strategies include adjusting the dose and/or dosing frequency of 
one or both interacting drugs, or replacing one agent with another drug with lower 
interaction potential. Often close clinical, virological and therapeutic drug monitoring is 
warranted.  
  
1.6.2 Pharmacogenetics  
Pharmacogenetics refers to genetic differences in metabolic pathways that can affect 
individual responses to drugs, both in terms of therapeutic effect as well as adverse 
effects [134]. Pharmacogenetics is a rapidly growing field of interest encompassing 
genetic variation in genes encoding drug transporters, drug-metabolizing enzymes and 
drug targets, as well as genes related to the action of drugs. Pharmacogenetics can be 
used to find genetic polymorphisms in the genes encoding proteins and enzymes 
involved in drug transport, metabolism and action that can predict the usefulness of a 
particular drug, increasing the number of responders and decreasing the number of 
subjects affected by adverse drug reactions. It is evident that the polymorphism of drug-
metabolizing genes has a high impact on inter-individual differences in drug response 
such as inhibition and induction of drug metabolism among a variety of other things 
[135]. Applications in pharmacogenetics are substantial and provide clinicians with 
information that could facilitate an individualized therapy of patients, both with respect 
to the choice of drug and the dose of a specific drug. Pharmacogenetics is, however, 
still in the beginning; knowledge about genetic variation at the level of drug 
metabolism is extensive, whereas the knowledge about inter-individual differences in 
the function of drug transporters and drug targets is scarcer.  
Valuable databases have been created that store information on the various drug 
receptors, drug transporters and drug-metabolizing enzymes that can be used to find 
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characterized haplotypes, specific single nucleotide polymorphisms (SNPs) and allele 
frequencies in various ethnic groups [136, 137]. There are 57 known active CYPP450 
genes in the human genome which are responsible for 70–80% of all phase I-dependent 
metabolism of clinically used drugs [138, 139]. The functional importance of the 
variant alleles varies and the frequency of their distribution in different ethnic groups is 
different. The polymorphic forms of CYPP450s are often responsible for the 
development of adverse drug reactions [140]. Four major phenotypes are known: poor 
metabolizers lacking functional enzyme, intermediate metabolizers being heterozygous 
for a defect allele, efficient metabolizers carrying two functional gene copies and 
ultrarapid metabolizers carrying more than two functional gene copies [141]. 
 
1.6.3 Rifampicin pharmacokinetics and pharmacogenetics 
Rifampicin is a semisynthetic antibiotic derivative of rifamycin. Absorption of 
rifampicin is reduced by about 30% when the drug is ingested with food. 
Rifampicin is widely distributed throughout the body and is present in effective 
concentrations in many organs and body fluids, including the cerebro-spinal fluid 
(CSF). Rifampicin is about 80% protein bound. Most of the unbound fraction is not 
ionized and, therefore, diffuses freely into tissues. After an oral administration of 
600mg of rifampicin peak concentration in plasma is reached in 2 to 4 hours [142-144]. 
Up to 30% of a dose of the drug is excreted in the urine and 60% to 65% in the faeces 
[145]. Rifampicin at therapeutic levels has demonstrated bactericidal activity and 
potent sterilizing effect against both intracellular and extracellular Mycobacterium 
tuberculosis organisms. Moderate rises in serum concentrations of bilirubin and 
transaminases, which are common at the outset of treatment, are often transient and 
without clinical significance, however, dose-related hepatitis can occur and could be 
potentially fatal. 
Rifampicin is a known inducer of the CYP450 enzymes such as CYP2B6, CYP3A, 
CYP2C19, CYP2C8, CYP2C9 and CYP1A2 [146-152]. Administration of rifampicin 
with drugs that undergo biotransformation through these metabolic pathways may 
accelerate elimination of co-administered drugs. 
 
1.6.4 Efavirenz pharmacokinetics and pharmacogenetics 
Efavirenz is a NNRTI and is used as part of HAART for the treatment of HIV-1 [34, 
146]. The oral bioavailability of efavirenz is affected by food as seen by increases in 
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peak plasma concentrations and area under the curve (AUC) of the drug after a normal 
to high calorie diet compared to a fasting state. It is primarily excreted in faeces, though 
a small proportion is also excreted via urine. Efavirenz is about 99.5% - 99.75% bound 
to plasma proteins, principally albumin. Its long half-life (40–55 h after repeated 
dosing) allows durable, long-lasting reduction in HIV RNA after once-a-day dosing 
(600 mg), presenting an advantage for treatment compliance and efficacy [151, 153]. 
Efavirenz is widely distributed in body compartments and is likely to be effective in 
protected tissues such as the central nervous system and testes [152, 154]. 
Efavirenz is extensively metabolized in the liver by oxidation via the CYP450 system. 
It has been shown to exhibit multiple interactions with CYP450 system such as being a 
substrate [153, 155], an inhibitor [156], and an inducer of CYP450 [157]. Further 
research has shown that efavirenz enhances its own metabolism after repeated dosing 
[153]. 
 
In vitro data together with in vivo evidence from literature strongly suggest that in the 
cytochrome P450 system the CYP2B6 is the main catalyst of efavirenz metabolism 
[158-160]. Efavirenz is primarily metabolized by hepatic CYP2B6, with some 
contributions from CYP2A6, CYP3A4/5 and UGT2B7 enzymes [160-162]. It is 
metabolized to inactive hydroxylated metabolites that include 7- and 8-
hydroxyefavirenz [155]. Based on in vitro data from human liver microsomes, the 7- 
and 8- hydroxyefavirenz on average account for 23% and 77% of overall efavirenz 
metabolism respectively. The 7-hydroxylation is mainly that accounts for 23% of 
efavirenz metabolism that is mediated by CYP2A6 while the 8-hydroxyefavirenz 
mediated by CYP2B6 [163-166].  
 
Inter-individual variability in efavirenz pharmacokinetics have been reported and 
linked to increased risk of central nervous system (CNS) toxicity or virological failure 
[167-169]. This variability has been linked to the CYP2B6 genetic variants. The 
CYP2B6 gene is highly polymorphic as reflected by 29 associated alleles, many 
suballeles, and SNPs [136, 170]. Of the variants identified so far, the CYP2B6*6 
haplotype defined by two non-synonymous SNPs, 516G>T (Q172H) and 785A>G 
(K262R), is clinically important because this allele or the SNP tagging it (G516T) 
occurs at high frequency in all ethnic populations (14–62%) and has been associated 
with functional consequences in expressed systems [170-176]. Subsequent to the 
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demonstration that CYP2B6 is the principal clearance mechanism of efavirenz in vitro, 
several studies have documented that the CYP2B6*6 allele or its tagging SNP results in 
increased risk for higher efavirenz exposure and/or adverse effects [170, 177, 178]. 
 
The frequency of CYP2B6-G516T among Japanese (3.3%) [178], Caucasian (6%) 
[179], Thai 8.9% [180], African-American (20%) [177] or African population (23%) 
[181, 182] further shows and confirms the differences among the ethnicities. Unlike the 
associations between CYP2B6 516G>T (SNP) and efavirenz exposure, other biological 
factors such as gender and body weight may play varying roles in the influence of 
efavirenz plasma concentrations. Some authors found higher efavirenz concentrations 
in women, while no such gender association was reported by other authors [167, 183, 
184] and likewise, with the association of body weight to plasma efavirenz 
concentrations [163, 183, 185].  
 
Clinical studies with HIV-infected patients have repeatedly shown that CYP2B6 
polymorphisms such as CYP2B6*6/*6 decrease efavirenz clearance and may be 
associated with CNS adverse effects [170]. The CYP2B6*6/*6 genotype is associated 
with an approximate 3-fold increase in efavirenz exposure compared with 
CYP2B6*1/*1 genotype [186]. In vitro studies showed that Vmax values for the 
formation of 8-hydroxyefavirenz were substantially decreased (by approximately 70%) 
in human liver microsomes (HLMs) with CYP2B6*6/*6 genotype versus HLMs with 
CYP2B6*1/*6 and CYP2B6*1/*1 genotypes [187]. The low clearance of efavirenz in 
CYP2B6*6/*6 haplotype has been associated with a reduced CYP2B6 protein 
expression in the liver [158].  
 
1.6.5 Efavirenz and rifampicin pharmacokinetics and pharmacogenetics 
Despite its well-known interaction potential via induction of the CYP450, rifampicin is 
commonly used in the treatment of HIV/AIDS patients co-infected with TB. Efavirenz-
based antiretroviral regimen is preferred during rifampicin-containing antituberculous 
therapy. The adult fixed dose of 600 mg per day is associated with wide inter-
individual variability in plasma concentrations, as well as clinical outcome and this 
variability is even greater during co-administration with rifampicin or rifampicin-
containing antituberculous therapy suggesting a variable degree of drug–drug 
interaction [167-169, 188-190]. 
The available pharmacokinetic data showed that rifampicin reduced the area under the 
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concentration–time curve (AUC) of efavirenz by 13 – 25% [191-193]. While some 
authors reported a 7 − 13-fold induction, others found only 2.5-fold increase in activity 
[194-196]. The proposed mechanism of the rifampicin–efavirenz interaction is 
induction of CYP3A and CYP2B6. Rifampicin enhances efavirenz metabolism probably 
via induction of CYP2B6-mediated 8-hydroxylation, and 8-hydroxyefavirenz exists 
primarily as a conjugate in plasma and urine samples. 
 
The reduction of efavirenz during rifampicin co-administration led some experts to 
recommend an increased efavirenz dose when co-administered with rifampicin [197, 
198]. It was recommended that the approximate 20% decrease in efavirenz in the 
presence of rifampicin would be overcome by increasing the dose to 800 mg/day from 
the usual 600mg/day [191, 198]. Clinically, efavirenz 800 mg/day was used in patients 
with HIV-TB co-infection on rifampicin-containing therapy but the increased dose did 
not show superior virologic suppression rates [199-201]. Rather, the increased dose was 
associated with higher frequencies of CNS and hepatic toxicities associated with high 
efavirenz plasma concentrations. Recent studies have shown that individuals with the 
CYP2B6 516 TT genotype are at risk of high efavirenz plasma exposures even in the 
presence of rifampicin-containing therapy [181, 202]. Thus, increase in efavirenz dose 
during rifampicin-containing therapy may not be necessary in individuals with slow 
metabolizing phenotype.  
 
  29 
2 RATIONALE 
HIV is now considered a chronic disease and the widespread use of HAART is destined 
to improve the quality of life of HIV infected individuals. As seen over the years, 
comorbidity with TB is abundant. With the presence of effective therapy for both HIV 
and TB, concurrent treatment is complicated due to drug-drug interactions. Due to these 
interactions, some scientists suggested an increase in efavirenz dose from the standard 
600mg/day to 800mg/day to counter the effects of reduced efavirenz concentrations 
when co-administered with rifampicin during TB treatment [191, 198, 203, 204]. 
Alternatively, other scientists suggest that the standard efavirenz dose of 600mg/day is 
adequate in HIV positive patients receiving concomitant HAART and anti-TB therapy 
[192, 205, 206]. Thus an increased dose of EFV when used with RIF may be optimal in 
some populations whereas in other populations such general recommendation may 
result in more adverse event without better treatment outcome. 
 
Currently, there is little data available on the optimal regimens for concomitant 
treatment of TB and HIV in Africans due to wide genetic heterogeneity. It is known 
that there is a higher frequency of CYP2B6 defective alleles in African populations, and 
the degree of interaction between EFV and RIF varies between populations based on 
these polymorphisms. Co-treatment with efavirenz and rifampicin could affect the 
clinical, immunological and virological outcomes of HIV disease as well as TB 
treatment outcomes. Knowledge how to co-treat HIV and TB effectively while 
minimizing risk of drug-drug interaction is crucial in Africa in general and Tanzania in 
particular.  
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3 OBJECTIVES 
3.1 BROAD OBJECTIVE 
To assess the clinical outcomes as a result of drug-drug interactions during HIV/TB co-
treatment based on pharmacokinetic and pharmacogenetic aspects of interactions 
between rifampicin and efavirenz. 
 
3.2 SPECIFIC OBJECTIVES 
Paper I – to describe the socio-demographic and clinical features of patients enrolled at 
the care and treatment clinic at Muhimbili National Hospital following the free roll out 
of anti-retroviral drugs that was started in Tanzania in 2004 and assess the impact this 
free roll out has had on HIV. 
 
Paper II – Here we describe the socio-demographic characteristics, clinical 
presentation and associated mortality of two cohorts of patients, those who are HIV 
infected only and those who are HIV positive and co-infected with TB: to describe the 
socio-demographic characteristics, clinical profile and associated mortality of patients 
with HIV and HIV-TB co-infection. 
 
Paper III – to study factors influencing efavirenz auto-induction and the resulting 
effects on long-term efavirenz exposure, by comparing the changes in plasma efavirenz 
concentrations and metabolic ratio (MR) between week 4 and week 16 of therapy in 
HIV only patients in Tanzania based on gender and pharmacogenetic influences.  
 
Paper IV – To investigate the timing, incidence, clinical presentation, 
pharmacokinetics and pharmacogenetic predictors for antiretroviral and anti-
tuberculosis drug induced liver injury (DILI) in HIV patients with or without TB co-
infection. 
 
Paper V – To determine the incidence, clinical presentations and predictors for 
neuropsychiatric manifestations of efavirenz based antiretroviral therapy (HAART) 
with or without concomitant rifampicin based anti-tuberculosis treatment. 
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4 METHODOLOGY 
4.1 PAPER I 
The HIV CTC of Muhimbili National Hospital (MNH), in Dar es Salaam, Tanzania 
was set up in June 2004. The clinic was part of the National HIV care program that was 
started countrywide to provide care and treatment including provision of free ARV's. 
Patients' clinical information at the clinic was monitored using a clinic visit form. This 
information was and is still being regularly entered into an HIV database.  
 
For the purposes of our study, we used the data of patients enrolled between June 2004 
and September 2008. Eligible patients for this analysis were those aged 18 years and 
above with complete data. Incomplete data for this analysis included all individuals 
whose identification was in doubt, i.e. names, age and sex were not indicated or were 
actually in doubt. Also, incomplete data included all those who at baseline had no 
clinical information in their records and had no baseline CD4 counts nor clinical HIV 
staging. Individuals missing any one of these important variables were excluded.  
 
The clinic enrolled HIV positive patients referred from voluntary testing and 
counselling centres as well as hospitals in and around Dar es Salaam. At enrolment a 
structured first-visit form was used to collect patients' social demographic and clinical 
information, physical findings and anthropometric measurements. Opportunistic 
infections were diagnosed on the basis of standard clinical definitions and individual 
laboratory investigations. CD4 T-lymphocyte counts were determined using FACS 
Count System (Becton Dickinson, San Jose, CA, USA) at the Central Pathology 
Laboratory in MNH. HIV disease severity was categorized using the WHO HIV 
disease staging whereby stage I and II was categorized as mild disease, stage III as 
moderate disease and stage IV was categorized as severe disease. Immune suppression 
as indicated by CD4 T-cell counts was divided into < 100 cells/µL, 100-200 cells/µL 
and > 200 cells/µL.  
 
4.2 PAPERS II-V 
4.2.1 Study setting and population 
This was a prospective study conducted at 3 different sites all within Dar es Salaam, 
namely MNH, Infectious Disease Centre (IDC) and Mwananyamala District Hospital.  
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Patients enrolled in the study included: Newly diagnosed HIV-infected patients who 
were naïve to antiretroviral therapy, consenting adults ≥18 years of age, CD4 cell count 
<200cells/µL with excluded TB disease at recruitment. These patients were referred to 
as HIV-only. Another group of patients were those who were newly diagnosed to have 
TB disease (pulmonary or extrapulmonary), with concomitant HIV infection and naive 
to antiretroviral therapy, with a CD4 cell count <200cells/µL. These patients with HIV 
and TB co-infection were referred to as HIV-TB. We excluded pregnant women, 
prisoners, haemoglobin  < 8 gms/dL, a history of treated TB infection within the last 5 
years and severely ill patients.  
 
HIV was diagnosed using the algorithm set forth by the Ministry of Health and Social 
Welfare (MoHSW) based on the serial testing strategy recommended by WHO (two 
rapid tests, ELISA, and Western Blot). TB was defined as a definitive or presumed 
clinical illness consistent with TB symptoms and signs. The definitive diagnosis was 
made if sputum smear was AFB positive or if histology was consistent with the 
presence of TB granulomas. A presumptive diagnosis of TB was established if the 
patient presented with symptoms suggestive of TB (fever, cough, weight loss, night 
sweats over 2 weeks duration) even if sputum smears were negative for AFB. This was 
done following the NTLP algorithm, whereby patients presenting with such symptoms 
initially receive broad spectrum antibiotics for at least two weeks. In case of poor 
response to antibiotics a sputum smear was repeated and chest radiograph done. An 
abnormal chest radiograph with persistent symptoms despite treatment and in the 
absence of other causes of such symptoms, patients were started on anti TB with the 
presumptive diagnosis of AFB smear negative TB. 
 
4.2.2 Recruitment and follow up 
After informed consent and appropriate pre-test counselling patients were seen at pre-
determined intervals where clinical and laboratory assessments were done. All 
information was recorded into a case report form (CRF) and later entered into a 
Microsoft Access Database. The HIV only patients were seen at weeks 0, 1, 2, 4, 8, 12, 
16, 24, 36 and 48. At week 0 the demographic characteristics, a detailed history of 
present and past illnesses was taken along with a general physical examination. 
HAART was initiated at week 0 for the HIV only, whereas for those with HIV-TB co-
infection, after 4 weeks of anti-TB treatment HAART was initiated. For those co-
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infected with HIV and TB scheduled visits were on weeks 0, 2, 4, 6, 8, 12, 20, 28, 40 
and 52.   Education on the treatment regimens being provided and potential side effects 
and toxicities of the drugs was given along with adherence counselling by the study 
nurse. Assessment of drug adherence (to either HAART alone or HAART plus anti-
TB) was done at each visit and patients were encouraged to have treatment assistants or 
use alarms as methods of enhancing adherence. 
 
The study physicians did clinical evaluations for any adverse event and patient progress 
at every clinical visit. New TB diagnosis in HIV-only patients or worsening of TB 
symptoms in HIV-TB patients was noted and recorded in the CRFs. A verbal autopsy 
questionnaire was administered by the clinician to the relatives of those reported to 
have died during the study period. This questionnaire was administered in order to 
ascertain the probable cause of death in a situation where conduct of a real autopsy was 
not possible. For patients who missed their scheduled clinic visits telephone calls were 
placed to these patients to determine their whereabouts and appointments were re-
scheduled and they were encouraged to visit the clinic. For those who were lost to 
follow up, a home based care (HBC) worker was sent to follow this patient up at their 
given residence addresses. 
 
Patient follow up and treatment chart 
 
Key:  Anti TB – Time point (week) when anti TB in initiated 
 HAART – Time point when HAART is initiated 
EFV – Time points when blood is collected for plasma efavirenz   measurement 
 
 
  34 
4.2.3 Laboratory investigations  
The laboratory investigations were done according to the same clinical schedule in both 
groups. The routine laboratory testing was performed at the Central Pathology 
Laboratory in MNH, including complete blood count, CD4 cell count, viral load 
assessment, and serum biochemistry. In addition hepatitis B surface antigen, hepatitis C 
serology and venereal disease research laboratory (VDRL) was done. The serum 
biochemistry was determined using a COBAS MIRA chemistry analyzer (GMI, MI, 
USA) after it was calibrated. The determination of hepatitis B surface antigen (HBsAg) 
and anti-hepatitis C virus IgG antibody (anti HCV) was done using the antibody 
capture ELISA (Adaltis – EIAgen kit).  
 
Genomic DNA was isolated from peripheral blood leukocytes using QIAamp DNA 
Maxi Kit (QIAGEN GmbH. Hilden. Germany). Genotyping was carried out at the 
Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska 
University Hospital-Huddinge, Karolinska Institutet, Stockholm, Sweden. 
Genotyping for SNPs were done by real time PCR using pre-developed Taqman 
assay reagents for allelic discrimination (Applied Biosystems Genotyping Assays) 
according to the manufacturer’s instructions. Allelic discrimination reactions were 
performed using TaqMan® (Applied Biosystems, CA, USA) genotyping assays with 
the following ID number for each SNP: (C__7586657_20 for ABCB1 3435C>T 
rs1045642, C__11711730_20 for CYP2B6 c.516G>T rs3745274 [CYP2B6*6], 
C__26201809_30 for CYP3A5 6986A>G rs776746  [CYP3A5*3], C__30203950_10 
for CYP3A5 g.14690G>A rs10264272 [CYP3A5*6], C__32287188_10 for CYP3A5 
g.27131_27132insT  rs41303343  [CYP3A5*7] on ABI 7500 FAST (Applied 
Biosystems, Foster City, CA). The final volume for each reaction was 10µl, 
consisting of 2x TaqMan Universal PCR Master Mix (Applied Biosystems), 20 X 
drug metabolising genotype assay mix and 10 ng genomic DNA. The PCR profile 
consisted of an initial step at 50°C for 2 min and 50 cycles with 95°C for 10 minutes 
and 92°C for 15 sec. Genotyping for SLCO1B1 388A>G (rs2306283) and 521T>C 
(rs4149056) was done using LightCycler® based method as described previously 
[207]. Haplotype analysis was done using Haploview v.4.1 software. 
 
On the 4th week of efavirenz-based HAART, 8 ml of blood were collected 16 hrs post 
efavirenz dosing, centrifuged, and 2 mL plasma aliquot was taken and stored at -80°C 
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for determination of efavirenz and its metabolite concentration. Plasma samples were 
sent in dry ice to the Department of Clinical Pharmacology and 
Pharmacoepidemiology, University of Heidelberg. Germany. The determination of 
plasma Efavirenz and 8-hydroxyefavirenz concentrations by LC/MS/MS was 
performed as described previously [208, 209]. The lower limits of quantification in 
plasma were 10.0 ng/mL for efavirenz and 0.4 ng/mL for 8-hydroxyefavirenz.  
 
4.2.4 Treatment 
All HIV patients in the present study received efavirenz based HAART together with 
two NRTIs. Efavirenz	  was available as a 600 mg tablet for oral administration to be 
used once daily at bedtime. The nucleoside back bone was either zidovudine (300mg) 
plus lamivudine (150mg) twice daily or stavudine (30mg) plus lamivudine (150mg) 
also twice daily. The choice of which NRTI backbone to use was left to the decision of 
the attending clinician.  
HIV patients co-infected with TB, they were initiated on rifampicin containing anti-TB 
treatment for the first 4 weeks, after which HAART will be added on to their treatment. 
The TB treatment followed the WHO and NTLP guidelines with DOTS divided in two 
phases. The Intensive Phase of anti-TB therapy consisted of 2 months treatment with 4 
drugs namely rifampicin (150mg), isoniazid (75mg), pyrazinamide (400mg) and 
ethambutol (275mg) in fixed dose combinations (FDC), where dosage depended on the 
patient’s body weight. The Continuation Phase consisted of 4 months with 2 drugs, 
namely rifampicin and isoniazid also in a fixed dose combination. Cotrimoxazole 
(960mg once daily) prophylaxis was provided to the patients. Any other treatment that 
was given in addition to the study treatment during the study was documented in the 
CRF’s.   
 
4.3 ETHICAL CONSIDERATIONS  
Ethical permit to conduct the study for paper I was obtained from Muhimbili University 
College of Health Sciences (MUCHS) under the title “The study of enhancing 
adherence to antiretroviral drugs in the management of HIV/AIDS patients in 
Tanzania”. 
Ethical approvals for papers II-V were covered under the ethical permit titled 
“Optimization of Tuberculosis and HIV co-treatment in Tanzania and Ethiopia: 
Pharmacokinetic and pharmacogenetic aspects of drug-drug interactions between 
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rifampicin and efavirenz” obtained from Muhimbili University of Health and Allied 
Sciences (MUHAS), Tanzania and the Karolinska Institutet, Sweden. 
Prior to recruitment of the study participants, we obtained a written informed consent 
from each participant. 
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5 RESULTS AND DISCUSSION 
5.1 PAPER I 
Since the CTC clinic at MNH was set up in June 2004 up to September 2008, there 
were a total of 4108 HIV patients enrolled into the clinic.  A total of 2542 patients were 
enrolled between 2004-2005 and a further 1566 were enrolled between 2006-2008.  We 
excluded patients who had incomplete data. After exclusion, a total of 2408 patients 
were used for analysis. The excluded patients presented with similar characteristics to 
those included in the analysis like mean ages, gender distribution and WHO clinical 
staging.  
 
The overall median age at enrolment was 37 years, with males being significantly older 
(p = 0.003) and with most patients (62.7%) being below 40 years of age. This indicates 
that the young people below the age of 40 years accounted for the majority of clinic 
attendees in keeping with earlier reported national and global findings on the age group 
of patients most affected with HIV. There were twice as many females compared to 
males who were enrolled into the clinic (ratio 2.2:1). Significant differences were seen 
in the distribution of marital status between those enrolled 2004-2005 and 2006-2008 
with most patients (47.1%) being married, and this was true among both male and 
female patients.  The mean body mass index (BMI) of the studied patients was 22.8 ± 
4.6 kg/m2 though females presented with slightly higher BMI compared to the males 
(23.3 ± 4.8 vs 21.8 ± 4.0).  
 
At presentation to the clinic patients who were enrolled earlier were sicker than those 
enrolled later (2004-2005); 62.4 % were WHO stages I and II, 26.2% stage III and 
11.3% stage IV compared to (2006-2008) 78.6% were WHO stages I & II, 16.5% stage 
III and 4.9% stage IV respectively (p ≤ 0.001). Two thirds (65.7%) of all patients had 
CD4 cell counts below 200 cells/µL, of whom more than half had CD4+ T lymphocyte 
counts below 100 cells. Although patients who were enrolled to the clinic had severe 
immunosuppression, those enrolled during the first years of the program were found to 
be even more immunocompromised as compared to those enrolled later (127 cells /µL 
[IQR 174] versus 167 cells/µL [IQR 256] (p<0.001). This was also true with clinical 
presentation, where more patients were symptomatic at the beginning of the program 
(2004-2005) compared to the period 2006-2008. The number of symptoms at enrolment 
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was linearly inversely related to the level of CD4 cell counts. This difference in 
immune status and clinical characteristics could be explained by the easy access of 
ARVs which could have increased awareness and reduced stigma of the disease thereby 
leading to early presentation to HIV clinics. 
 
Women had significantly higher baseline CD4 cell counts and BMI compared to their 
male counterparts. The reason why males presented with lower CD4 cell counts was 
not clear from this study, however we can only speculate that males presented late due 
to stigma which was probably higher among men as compared to females. The other 
reason could be the difference in health seeking behaviour of men compared to women 
as seen by higher numbers of women enrolled at clinics. Approximately a fifth of the 
patients reported to have suffered from TB over the past five years. This is in keeping 
with the fact that TB is the most common infectious disease among HIV infected 
patients and that it is highly prevalent in sub Saharan Africa.  
 
Prior to free access to ARVs, some of the patients who came to the clinic were not 
naïve to HAART as they had acquired them through private pharmacies. The absence 
and difficulty to access appropriate treatment early in the program sometimes led to 
some patients (2.7%) seeking alternative forms of treatment such as traditional 
medicines and spiritual healing. With increased access to HAART, there was a 
reduction of patients who sought out alternative treatment options as seen in patients 
who were enrolled later in the program. However, despite the improved access to 
ARVs, the pattern of clinical presentation has not changed much with time because 
patients still present late with severe immunosuppression to the HIV clinics. 
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5.2    PAPERS II-V 
Flow Chart showing patient recruitment and follow up 
 
 
Key: LTFU – Lost to follow up 
 ETB – Patients were withdrawn due to new TB diagnosis  
 Withdrew – Patients voluntarily withdrew themselves from the study 
 Died – Patients that died within the study period 
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General baseline results for the cohort  
A total of 486 HIV-1 infected individuals were recruited of whom 255 (53%) had HIV 
only while 231 (47%) have HIV and TB co-infection. There were significantly more 
females among the HIV only patients compared to the HIV-TB patients (p<0.001). 
Patients with HIV-TB co-infection had a lower median BMI of 19.4 kg/m2 compared to 
21.3 kg/m2 among patients with HIV alone (p<0.001). Past history of opportunistic 
infections revealed that 13% had suffered from TB and 12% had a history of herpes 
zoster infection presenting with post herpetic scars. 
 
More (40%) of the HIV-TB co-infected patients presented with Karnofsky scores of 
≤80% compared to those with HIV alone (13%). The most common presenting 
symptoms were weight loss (44.2%), cough (39.9%), fever (35.4%), loss of appetite 
(29.6%), headache (25.7%) and skin rash (25.3%). The most common clinical findings 
were pruritic papular eruption (PPE) (18.9%), lymphadenopathy (18.7%) and oral 
candidiasis (15.0%). Patients with HIV-TB co-infection had a significantly lower mean 
haemoglobin level (9.97 ± 1.55) compared to those infected with HIV alone (10.62 ± 
1.73). The median CD4 cell counts and log transformed viral loads were similar in both 
HIV only patients and those co-infected with TB. Among the HIV-TB co-infected 
patients 67% were sputum positive for AFB with the remaining 33% being AFB 
negative or having EPTB.  
 
A combination of zidovudine, lamivudine and efavirenz was initiated in 83.1% of the 
patients with HIV alone while only 49.3% of the HIV-TB co-infected patients were 
initiated with the same combination. This was due to the low baseline haemoglobin 
levels among those with HIV-TB co-infection.  
 
General follow up results of the cohort. 
At the end of the study (48 weeks after HAART initiation) we managed to successfully 
follow up a total of 161 HIV only patients and 126 HIV-TB patients. In the HIV only 
patients a total of 9.8% withdrew themselves from the study and 9.4% were lost to 
follow up whereas among the HIV-TB patients 18.6% withdrew from the study and a 
further 15.6% were lost to follow up. This proportion was higher, however not 
significantly so in the HIV-TB patients. We believe that most patients tend to go back 
to regions of origin after initiation of treatment and improvement of their health. 
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During the follow up period there was a steady increase in the weight of both HIV only 
and the HIV-TB patients. This shows a clear benefit from HAART initiation as seen by 
the overall well being and functional status of the patient. This was also evident from 
few reported opportunistic infections among these patients. CD4 cell count is the single 
most important parameter in monitoring ART in HIV-infected individuals especially in 
resource-constrained countries like Tanzania [7, 210, 211]. There was a gradual 
increase in the CD4 cell counts in both the HIV-only patients and those with HIV-TB. 
The median CD4 counts at 12, 24, 36 and 48 weeks after HAART initiation among 
HIV only patients was 182, 199, 212 and 250 cells/µL respectively while in the HIV-
TB patients it was 200, 211, 251 and 274 cells/µL respectively. The most dramatic 
changes were seen within the first 12 weeks where the HIV only patients had a median 
increase of 92 cells/µL and 106 cells/µL in those with HIV-TB from their baseline 
levels. 
 
HIV viral load is a useful tool for monitoring of HAART [212]. It is not used routinely 
for monitoring HAART in resource-limited countries. In our study we were able to 
obtain results from 163 patients. A total of 32.5% (33.3% HIV only and 31.2% HIV-
TB) had detectable viral load (>50 copies/mL) at 48 weeks. Significant differences in 
mean log plasma efavirenz concentration at week 4 was seen between the patients who 
had virological failure (3.06 ± 0.63) and those who did not (3.28 ± 0.42) (p = 0.023). 
However, no significant differences were observed at week 16. The difference in 
efavirenz concentrations was not apparent when stratified by disease status (i.e. HIV 
only vs HIV-TB) at both weeks 4 and 16. Similarly, patients with virological failure 
had significantly lower median CD4 cell counts compared to those without failure 
(218cells/µL [IQR=224] vs 275cells/µL [IQR=203]) (p = 0.042), however when 
stratified by disease status, this difference was not significant. There were 
proportionately more patients with CYP2B6*1/*6 genotypes (48.8%) with treatment 
failure compared to those with *1/*6 and *6/*6 (39.0% and 12.2% respectively). 
 
5.3 PAPER II 
From the 486 recruited patients a total of 54 (11.1%) patients died during the 48 week 
follow up period after HAART initiation. This compares well with other studies that 
showed similar rates of mortality [213, 214]. Proportionately there were more males 
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(13.1%) [20 deaths/100person years (py)] who died compared to females (9.6%) [14 
deaths/100py]. Of the 54 patients who died, 28 [16 deaths/100py] had HIV only and 26 
[17/100py] had HIV-TB co-infection.  This is of interest since the mortality rate in the 
HIV only patients and those with HIV-TB were similar. Studies have shown that with 
good anti-TB therapy, mortality among HIV-TB patients need not be higher than those 
with HIV only [215, 216]. 
 
Of the patients who died, 54% were WHO clinical stage III and 11% were WHO 
clinical stage IV. There were statistically significant differences in BMI among those 
patients who died compared to those who didn’t (19.3±3.6 versus 21.1±4.2) (p=0.003). 
Likewise, highly significant differences were seen in the median baseline CD4 cell 
counts between patients who died and those who didn’t. Patients who died had lower 
CD4 counts that those who didn’t (48 [IQR=101] versus 98 [IQR=116]) (p<0.001). 
Viral load levels were significantly higher among patients who died, compared to those 
who didn’t (p=0.015). 
 
The median time to death among these patients was 13 weeks [17 deaths/100py]. In the 
HIV only patients 16 (57.2%) died in the first 16 weeks of HAART initiation. A large 
proportion (21%) of the patients died towards the last third of the follow up period. 
Among the 26 HIV-TB patients who died, 6 (23%) died while still on anti-TB therapy 
before HAART was initiated at the 4th week of treatment. Following HAART initiation, 
46.2% died while on anti-TB treatment and HAART, and a further 8 (30.8%) died after 
the completion of TB treatment while continuing with HAART. However, in both the 
HIV only and those with HIV-TB over 50% died within the first 4 months of HAART 
initiation. Improvement of immune status associated with HAART could explain the 
lower mortality rates during the later periods of the study. 
 
After analysing the verbal autopsy reports from the relatives of the deceased and 
hospital records, there was no specific pattern seen in either the HIV only or the HIV-
TB patients and the symptoms at death showed a wide variation. Multivariable analysis 
showed that clinical predictors of mortality were the presence of oral candidiasis, 
Kaposi’s sarcoma and low Karnofsky scores. Laboratory parameters that were 
predictors of mortality include low baseline white blood count (WBC) and CD4 cell 
counts. The risk factors for mortality are those of severe immunosuppression due to late 
presentation to the CTC. 
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Self-reported adherence to HAART was 98% over the past week for HIV only patients 
and 97% for those with HIV-TB co-infection on HAART and anti-TB therapy. The 
good adherence rates may be due to persistent counselling given to patients on 
adherence during each clinic visit and the encouragement to have treatment assistants 
[217]. In this study 4.7% of the HIV only developed active TB after HAART initiation. 
These were classified as HAART-related TB with similar prevalence’s to those 
reported in other studies [218, 219]. Among HIV-TB patients on anti-TB who were 
started on HAART only, 3% of the patients developed exaggerated features of TB, 
which we defined as TB IRIS. These features were in the form of increased fever 
episodes and enlargement of lymph nodes.  
 
5.4 PAPER III 
A total of 255 HIV only patients were recruited into the study. Of these only 129 
patients were used for analysis due to the available data on efavirenz plasma 
concentrations at both time points (i.e. 4th week and 16th week after HAART initiation). 
The mean age of these patients was 39.6±9.1 years, with the male to female ratio of 
1:2.1. The median BMI and baseline CD4 cell counts among these patients was 23(20-
26) and 103 (44-160) cells/µL respectively. The allele frequencies from 120 patients for 
CYP2B6*6, CYP3A5*3, CYP3A5*6, CYP3A5*7 and ABCB1 were 39.6%, 21.7%, 
18.8%, 11.3% and 15.4% respectively. For the CYP2B6 the genotype frequencies for 
*1/*1, *1/*6 and *6/*6 were 37.5%, 45.8% and 16.7% respectively.  
 
The proportion of subjects with sub-therapeutic efavirenz plasma levels (<1 µg/ml) 
increased by 57% at week 16 as compared with the value at week 4, whereas the 
proportion of those with risk for toxicity (>4 µg/ml) decreased by 44%. The magnitude 
of change was influenced mainly by CYP2B6 genotype. The most affected group was 
patients with CYP2B6*1/*1 followed by those with CYP2B6*1/*6 genotype whereas 
among CYP2B6 slow metabolizers (2B6*6/*6), there was no significant change in the 
plasma efavirenz concentrations between weeks 4 and 16. During HAART the levels of 
efavirenz decrease and those of this metabolite (8-hydroxyefavirenz) increase; this led 
to a lowered efavirenz concentrations at week 16 of therapy.  
 
Our results indicate that the enzymatic activity of CYP2B6 at week 16 of therapy is 
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higher than at week 4 thereby suggesting that the effect of efavirenz auto-induction in 
reducing efavirenz plasma exposure continues up to week 16 of therapy. The extent of 
this change in plasma concentrations of efavirenz, its metabolite (8-hydroxyefavirenz) 
and the metabolic ratio between weeks 4 and 16, were higher among CYP2B6*1 
carriers than in those with the CYP2B6*6/*6 genotype. This implies that patients who 
are carriers of the functional enzyme are more likely to experience autoinduction of 
efavirenz to an extent that may have consequences for the long term HAART outcome 
especially in the CYP2B6 extensive metabolisers (CYP2B6*1/*1). 
 
The relevance of the CYP3A5 genotype in affecting the extent of enzyme inducibility 
was reflected among CYP2B6 slow metabolizers. In the CYP2B6*6/*6 group, carriers 
of one or two CYP3A5*1 alleles had higher 8-hydroxyefavirenz values at week 16 
compared to those lacking the allele. No changes were seen in patients lacking both 
CYP2B6*1 and CYP3A5*1 alleles, showing that CYP3A5 is an alternative pathway in 
efavirenz metabolism. Gender had no impact on the changes in the proportion of 
patients within the different efavirenz therapeutic ranges, plasma efavirenz levels or the 
metabolic ratios at week 4 and 16.  
 
5.5 PAPER IV 
A total of 473 patients with complete laboratory data were used for analysis, of whom 
253 were HIV only and 220 were those with HIV-TB co-infections. As per our case 
definition of DILI based on one or more AST/ALT levels ≥ 2 X UNL, 37 patients 
(7.8%) developed drug induced liver injury (DILI). Fifteen (5.9%, 6.3 per 1000 person-
week) patients developed DILI among HIV only patients while twenty-two (10.0%, 
10.7 per 1000 person-week) HIV-TB patients developed DILI, an almost 2-fold 
incidence of DILI among the HIV-TB patients compared to those with HIV only. These 
results are similar to those reported elsewhere describing that concomitant HAART and 
anti-TB therapy exacerbates the incidence of DILI [220, 221]. The DILI was transient, 
with AST and/or ALT levels coming back to within normal limits by 12 weeks of 
HAART with no treatment modification required for patients with DILI. The low 
incidence and tolerability of DILI among Tanzanian HIV patients is comparable to 
other reports from Africa [220, 222]. 
 
Proportionally more males developed DILI compared to females. Patients who 
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developed DILI had lower baseline CD4 cell counts compared to those without DILI 
(p=0.056). No association with DILI was seen among patients who used fluconazole or 
consumed alcohol. In a subgroup of HIV-TB patients, pronounced DILI was observed 
before the introduction of HAART indicating that rifampicin may contribute to the 
hepatotoxicity, however in the majority of cases the DILI appeared later in conjunction 
with the introduction of efavirenz.  
 
The prevalence of HBsAg and anti-HCV antibodies was 10.4 % and 3.1% respectively 
in the cohort, however, a significant 25% of the patients with positive HCV antibody 
developed DILI (p=0.028). We observed that hepatitis C infection was a significant risk 
factor for the development of DILI rather than hepatitis B. All our study subjects 
received lamivudine as part of HAART and this might lead to alleviating HBV co-
infection as a risk factor for DILI. Significant differences in the distribution of CYP2B6 
genotype were seen between patients with and without DILI. The frequency of 
CYP2B6*6 (c.516TT) and CYP2B6*6/*6 genotype was overrepresented among patients 
with DILI. The variant CYP2B6*6 allele was associated with higher efavirenz plasma 
concentration and in our study it was found to be a risk factor for DILI, however, 
plasma efavirenz concentration on its own was not a risk factor. Interestingly, efavirenz 
concentrations were higher in patients with low BMI in the HIV only patients receiving 
efavirenz-based HAART whereas no such difference in BMI was seen in HIV-TB 
patients receiving rifampicin and efavirenz.  
 
Of the 54 DILI patients a total of 7 (13%) died during the study period with median 
time to death being 4 weeks. Causes of death among these patients were not associated 
with DILI as shown in verbal autopsy reports. Gradual and comparable increases in 
CD4 cell counts and body weight were seen among patients with and without DILI 
from baseline to 12 weeks after HAART initiation. Despite the high pill burden 
especially in those on both anti-TB and HAART and potential toxicity, patients’ self-
reported adherence was high (>95%). 
 
5.6 PAPER V 
Data from 458 patients (243 HIV only and 215 HIV-TB) was used for analysis as these 
had documentation on the neuropsychiatric manifestations. Of the 458 patients, 264 
(57.6%) had some form of neuropsychiatric manifestations during the 16-week study 
period comparable to incidences reported from other studies [151, 223, 224]. 
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Significant differences in the presence of neuropsychiatry manifestations were seen 
between the HIV only compared to those with HIV-TB (66.7% and 47.4% 
respectively) (p<0.001). HIV only patients were more symptomatic compared to the 
HIV-TB patients where just over a third (33.4%) of the HIV only compared to over half 
(52.6%) of those with HIV-TB did not present with any neuropsychiatric 
manifestations. However, for symptomatic patients, higher severity was reported in 
general in those with HIV only compared to those with HIV-TB. This difference in 
severity of symptoms between the HIV only and HIV-TB was statistically significant 
(p<0.001). 
 
The median time to neuropsychiatric manifestations was 2 weeks during the 16 week 
follow up. However, in the HIV only patients, the median time to manifestations was 1 
week after HAART initiation while in patients with HIV-TB this was seen at 6 weeks 
(i.e. 2 weeks after HAART was initiated). No differences were seen in median 
efavirenz concentrations and the metabolite 8-hydroxyefavirenz among patients with 
and without neuropsychiatric manifestations at weeks 4 and at 16 weeks respectively. 
There were no gender differences between patients with and without neuropsychiatric 
manifestations. There were no differences in plasma efavirenz concentrations between 
those with and without neuropsychiatric manifestations when stratified by disease 
status (HIV only and HIV-TB). The single most significant predictor of 
neuropsychiatric manifestations was the use of efavirenz only, compared to use of 
efavirenz and rifampicin. Baseline age, BMI and CD4 did not differ among patients 
with and without neuropsychiatric manifestations 
 
The group 1 symptoms of depression and anxiety seem to occur in both HIV only and 
HIV-TB patients despite the absence of efavirenz in the beginning of the evaluation in 
the HIV-TB patients when they are on anti-TB alone. These symptoms were mild, and 
not specific to the known efavirenz neurotoxic side effects. The higher proportion of 
symptoms in the HIV only could also be due to the stress brought on by psychological 
adjustment to recent HIV diagnosis. HIV disease status on its own is a risk factor for 
neuropsychological impairments despite the HIV stage [225, 226]. Patients with low 
CD4 nadir are also more likely to have these impairments as seen in our study where 
most of the patients had lower CD4 cell counts with a larger proportion having counts 
below 100cells/µL. Addition of efavirenz based HAART caused an increase in these 
symptoms in the first week of therapy. However, the waning off of these symptoms in 
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subsequent weeks could also be explained by the immune reconstitution as seen by 
increase in CD4 counts at 12 weeks, efavirenz auto-induction and the use of 
concomitant rifampicin in the HIV-TB patients. Despite presence of the 
neuropsychiatric manifestations, patients’ self-reported adherence to HAART in both 
the HIV only using HAART alone and the HIV-TB patients using both anti-TB therapy 
and HAART was over 95%.  
  48 
6 CONCLUSIONS 
The results of the study indicate that patients enrolled at HIV clinics around Dar es 
Salaam are predominantly women, and they present to the clinics fairly late with severe 
immunosuppression. The results also show that persons below the age of 40 were those 
most affected by the disease and that the time at presentation to the HIV clinics 
influences the clinical spectrum of symptoms and signs seen at the initial evaluation. 
Improved access to HIV care and treatment services has been associated with early 
presentation to the clinics in the course of the HIV disease. HIV related TB is high 
among patients attending HIV clinics.  
 
Mortality of HIV positive patients who are initiated on HAART is still considerable 
with mortality occurring early in the treatment duration. There was no significant 
difference in mortality between HIV only patients started on an efavirenz based 
HAART and the HIV-TB patients started on rifampicin-based anti TB therapy and 
efavirenz based HAART. Predictors of mortality were those of advanced disease such 
as low Karnofsky scores, low baseline CD4 cell count and low white blood cell count 
and the presence of opportunistic infections such as oral candidiasis and Kaposis 
sarcoma.  
 
We investigated the influence of pharmacogenetic variations on efavirenz 
concentrations among our patients. A little over 40% (42.2%) of the patients had the 
extensive metabolizer genotype. Our results indicate that CYP2B6 genotype determines 
not only the plasma efavirenz concentration at a given time point but also the long-term 
effect of efavirenz auto induction on plasma exposure. Individuals with the extensive 
metabolizer phenotype experience a pronounced efavirenz autoinduction effect which 
may influence the long term therapeutic outcome. The effect of efavirenz autoinduction 
on reducing plasma exposure continues up to week 16. The magnitude of change was 
influenced mainly by the CYP2B6 genotype with the most affected group being those 
with *1/*1(rapid metabolizers) followed by *1/*6 and lastly by those with *6/*6 (slow 
metabolizers) genotypes.   
 
Efavirenz-based HAART and rifampicin-based anti-TB DILI does occur in Tanzanian 
HIV patients, presenting early after HAART initiation. Despite these patients having 
DILI, in the majority of these patients the elevations of the liver enzymes was relatively 
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mild, transient and did not require any modification of the treatment regimens. The risk 
for developing DILI was attributed to a positive anti-HCV IgG antibody and the 
presence of CYP2B6*6/*6 genotype. Despite the presence of DILI, there is good 
tolerance to HAART and anti-TB therapy with good clinical and immunological 
outcomes. 
 
Incidence of neuropsychiatric manifestations due to efavirenz-based HAART is high in 
Tanzanian HIV patients. Despite a relatively high proportion of patients reporting 
neuropsychiatric manifestations attributed to efavirenz, these symptoms are transient 
and not severe. There is wide inter-patient variability in plasma EFV concentration as 
seen in differences in gender and CYP2B6 genotypes. The use of rifampicin-containing 
anti-TB therapy concomitantly with efavirenz decreases the risk of developing 
neuropsychiatric manifestations up to three times compared to those on efavirenz-based 
HAART. Plasma efavirenz concentrations at week 4 after HAART initiation, and the 
CYP2B6 genotype are not positively correlated with development of neuropsychiatric 
manifestations.  
 
A significant proportion of patients (32.5%) developed treatment failure. However, no 
differences were noted between the HIV only and HIV-TB patients. Both the HIV only 
and the HIV-TB patients showed comparable clinical and immunological outcomes. 
 
Overall, free access to HAART has greatly improved patients lives and clinical 
outcomes. The recommended efavirenz dose of 600mg when used with rifampicin 
shows similar clinical outcomes compared to those using efavirenz-based HAART 
alone in terms of toxicities (DILI and neuropsychiatric manifestations), immunological 
(CD4 cell counts) and virological (viral load) outcomes despite the pharmacokinetic 
and pharmacogenetic drug-drug interactions.  
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7 RECOMMENDATIONS  
More efforts need to be put in place to educate the public on the need for regular HIV 
testing so that the problem is caught earlier, allowing for subsequent appropriate 
accessibility to preventive and curative services.  
 
We recommend the reduction in national in-programme delays in initiating HAART for 
HIV patients with and without TB before the development of advanced HIV disease in 
order to reduce morbidity and mortality.  
 
We would like to encourage clinicians to avoid reluctance in combining HAART and 
anti-TB therapy for fear of toxicity in Tanzanian patients. As we saw from our study, 
co-treatment is tolerable among patients, with good clinical and immunological 
outcomes as well as good reported adherence to both HAART and anti-TB. 
 
Genotyping for CYP2B6 polymorphism in HIV clinics could help identify patients with 
poor metabolizer phenotype who are at risk of developing CNS toxicity, and the rapid 
metabolisers whose long-term therapeutic outcome might be compromised.  
 
Measurement of plasma efavirenz concentrations could assist in therapeutic drug 
monitoring to ensure patients are within therapeutic ranges to avoid suboptimal 
efficacious response or even the development of acquired drug resistance.  
 
The WHO recommended efavirenz dosage of 600mg daily can be used with rifampicin 
among Tanzanian patients without compromise to their treatment outcomes.  
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